Ohio State University Comprehensive Cancer Center
🇺🇸United States
Identification of Novel Genetic Factors That Contribute to Risk for Breast Cancer
Completed
- Conditions
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2023-01-25
- Target Recruit Count
- 4385
- Registration Number
- NCT00276120
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-12-21
- Last Posted Date
- 2015-04-30
- Target Recruit Count
- 45
- Registration Number
- NCT00267696
- Locations
- 🇺🇸
The Ohio State University & James Cancer Hospital, Columbus, Ohio, United States
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2017-12-26
- Target Recruit Count
- 57
- Registration Number
- NCT00230126
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-02-08
- Target Recruit Count
- 28
- Registration Number
- NCT00201721
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2015-06-30
- Target Recruit Count
- 22
- Registration Number
- NCT00201773
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2018-03-12
- Target Recruit Count
- 25
- Registration Number
- NCT00201877
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-12-06
- Target Recruit Count
- 80
- Registration Number
- NCT00201747
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2015-06-10
- Target Recruit Count
- 19
- Registration Number
- NCT00201799
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-04-27
- Target Recruit Count
- 8
- Registration Number
- NCT00201786
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-09-23
- Target Recruit Count
- 57
- Registration Number
- NCT00201734
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
© Copyright 2024. All Rights Reserved by MedPath